Jonathan is an IP litigator with particular experience in pharmaceuticals and life sciences.
Jonathan's core practice is assisting Global R&D based pharmaceutical companies meet their commercial aims in relation to their blockbuster drugs (both small molecule and biological medicines). Jonathan has acted for clients such as AbbVie, Eisai, Gilead, Sanofi and Takeda.
Jonathan uses his strong scientific background to work closely with his clients to prepare and implement multi-jurisdictional strategies by collaborating with lawyers across Europe and beyond. From his experiences handling such matters, Jonathan has developed a deep understanding of the pharmaceutical and life sciences sectors with particular specialism in issues concerning SPCs and market access, and has coordinated patent litigation in most European countries. He has collaborated and developed excellent relationships with leading IP counsel in numerous firms across the globe.
Jonathan also has extensive experience in both advising and acting in intellectual property disputes in the UK, including on issues of employee inventor compensation. He is either currently advising, or has recently advised, clients before all relevant forums in the UK: UK-IPO, High Court, Court of Appeal, Supreme Court and Courts of Justice of the European Union. In doing so, he has acted for major national and international clients in both enforcing and challenging intellectual property rights.
Jonathan has a doctorate in bio-organic chemistry supervised by Professor CJ Schofield at the University of Oxford. This doctorate covered a broad spectrum of scientific disciplines including chemistry, biochemistry, genetics and molecular biology. Jonathan also holds a Masters of Chemistry (First Class Honours) from the University of Oxford and a Diploma in IP Law from the University of Bristol.
Jonathan is a solicitor advocate with rights of audience in all civil proceedings in the UK.
Experience & expertise
- AbbVie in United Kingdom and multi-jurisdictional patent litigation regarding its leading its blockbuster anti-TNFα antibody Humira® (adalimumab)
- Sanofi in various commercially important matters including the pan-European defence and enforcement of the SPCs protecting irbesartan
- Unilever, on various patent related matters, including in relation to employee invention compensation
- Takeda in the pan-European defence and enforcement of patents relating to its successful multiple myeloma drug, Velcade
- Gilead in UK litigation regarding its leading blockbuster HIV therapy, Truvada® (tenofovir disoproxil and emtricitabine)
- Eisai in coordinating multi-jurisdictional patent litigation across Europe concerning Eisai's blockbuster drugs Aricept, an Alzheimer’s treatment, and Pariet, an anti-ulcer drug
- a global pharmaceutical company in coordinating its multi-jurisdictional enforcement strategy concerning its IP rights over a small molecule blockbuster drug
- a global pharmaceutical company in the successful defence of a high value arbitration concerning the royalties payable to a third party